Recombinant factor VIIa as an adjunct in nonoperative management of solid organ injuries in children

Area of Science:

• Pediatric Surgery
• Trauma Management
• Hematology

Background:

• Blunt solid organ injury in children can cause ongoing bleeding, often necessitating invasive treatments like angiography or surgery.
• Recombinant activated factor VII (rFVIIa) is a procoagulant agent explored for managing such critical bleeding scenarios.

Purpose of the Study:

• To evaluate the efficacy of recombinant activated factor VII (rFVIIa) in controlling persistent hemorrhage in pediatric patients with blunt abdominal trauma.
• To assess the potential of rFVIIa to reduce the need for invasive interventions and blood transfusions in this patient group.

Main Methods:

• A retrospective review of 8 pediatric patients with blunt abdominal trauma and persistent bleeding managed nonoperatively with rFVIIa.
• Patients received a single dose of rFVIIa (75-90 microg/kg, with one patient receiving 24 microg/kg).

Main Results:

• Successful hemostasis was achieved in all 8 patients following rFVIIa administration, without requiring further therapeutic interventions.
• Only 3 patients needed blood transfusions post-treatment; two with subarachnoid hemorrhages and one during pelvic fixation.
• No thromboembolic events were observed in any patient treated with rFVIIa.

Conclusions:

• Recombinant activated factor VII (rFVIIa) serves as a valuable adjunctive therapy for pediatric patients experiencing ongoing hemorrhage from blunt abdominal injuries.
• The use of rFVIIa may significantly decrease the requirement for invasive procedures and blood transfusions in managing pediatric blunt abdominal trauma.